Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Persantin New vs Commercial Formulation in Healthy Males
NCT02259998Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2001
- Primary completion
- Dec 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dipyridamole in thromboembolism (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration time curve from 48 to 58 hours and Maximum concentration from 48 to 58 hours. Started Oct 2001; status: completed.
02
Drugs
dipyridamole
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02259998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259998.